AU2008239598A1 - Administration of carboline derivatives useful in the treatment of cancer and other diseases - Google Patents

Info

Publication number

AU2008239598A1

AU2008239598A1 AU2008239598A AU2008239598A AU2008239598A1 AU 2008239598 A1 AU2008239598 A1 AU 2008239598A1 AU 2008239598 A AU2008239598 A AU 2008239598A AU 2008239598 A AU2008239598 A AU 2008239598A AU 2008239598 A1 AU2008239598 A1 AU 2008239598A1

Authority

AU

Australia

Prior art keywords

optionally substituted

alkyl

alkoxy

aryl

independently selected

Prior art date

2007-04-13

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• Discuss

• 206010028980 Neoplasm Diseases 0.000 title claims description 188
• 201000011510 cancer Diseases 0.000 title claims description 68
• 238000011282 treatment Methods 0.000 title claims description 41
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 27
• 201000010099 disease Diseases 0.000 title claims description 12
• 150000001875 compounds Chemical class 0.000 claims description 257
• 125000000623 heterocyclic group Chemical group 0.000 claims description 205
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 196
• 125000001424 substituent group Chemical group 0.000 claims description 191
• 125000003118 aryl group Chemical group 0.000 claims description 186
• 229910052736 halogen Inorganic materials 0.000 claims description 185
• 125000000217 alkyl group Chemical group 0.000 claims description 183
• -1 acetamino, thio Chemical group 0.000 claims description 181
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 175
• 150000002367 halogens Chemical group 0.000 claims description 174
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 171
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 171
• 229910052739 hydrogen Inorganic materials 0.000 claims description 134
• 239000001257 hydrogen Substances 0.000 claims description 123
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 109
• 125000001072 heteroaryl group Chemical group 0.000 claims description 96
• 125000004043 oxo group Chemical group O=* 0.000 claims description 65
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 58
• 125000003342 alkenyl group Chemical group 0.000 claims description 48
• 230000002401 inhibitory effect Effects 0.000 claims description 47
• 239000000203 mixture Substances 0.000 claims description 42
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 40
• 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 38
• 201000001474 proteinuria Diseases 0.000 claims description 37
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 34
• 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 33
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 31
• 150000002431 hydrogen Chemical class 0.000 claims description 31
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 31
• 239000008194 pharmaceutical composition Substances 0.000 claims description 31
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 31
• 239000003795 chemical substances by application Substances 0.000 claims description 30
• 230000014509 gene expression Effects 0.000 claims description 30
• 125000000304 alkynyl group Chemical group 0.000 claims description 29
• 230000036470 plasma concentration Effects 0.000 claims description 28
• DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 27
• 125000003277 amino group Chemical group 0.000 claims description 27
• 125000001188 haloalkyl group Chemical group 0.000 claims description 27
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 25
• 108090000623 proteins and genes Proteins 0.000 claims description 24
• 206010020772 Hypertension Diseases 0.000 claims description 23
• 125000005843 halogen group Chemical group 0.000 claims description 23
• 125000004193 piperazinyl group Chemical group 0.000 claims description 22
• 150000003839 salts Chemical class 0.000 claims description 22
• 239000012453 solvate Substances 0.000 claims description 22
• 210000002700 urine Anatomy 0.000 claims description 22
• 238000009472 formulation Methods 0.000 claims description 21
• 102000004169 proteins and genes Human genes 0.000 claims description 21
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 20
• 125000003386 piperidinyl group Chemical group 0.000 claims description 19
• 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 19
• 239000003814 drug Substances 0.000 claims description 18
• 108020004999 messenger RNA Proteins 0.000 claims description 18
• 238000013519 translation Methods 0.000 claims description 18
• 125000002883 imidazolyl group Chemical group 0.000 claims description 17
• 230000001404 mediated effect Effects 0.000 claims description 17
• 125000000335 thiazolyl group Chemical group 0.000 claims description 17
• 230000033115 angiogenesis Effects 0.000 claims description 15
• 230000036772 blood pressure Effects 0.000 claims description 15
• 208000035475 disorder Diseases 0.000 claims description 15
• HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 15
• 229960003881 letrozole Drugs 0.000 claims description 14
• 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 14
• 125000002757 morpholinyl group Chemical group 0.000 claims description 13
• 206010012689 Diabetic retinopathy Diseases 0.000 claims description 12
• 208000037976 chronic inflammation Diseases 0.000 claims description 12
• 230000006020 chronic inflammation Effects 0.000 claims description 12
• 150000002148 esters Chemical class 0.000 claims description 12
• 208000002780 macular degeneration Diseases 0.000 claims description 12
• 229910052799 carbon Inorganic materials 0.000 claims description 11
• 125000001041 indolyl group Chemical group 0.000 claims description 11
• 150000002632 lipids Chemical class 0.000 claims description 11
• 230000001594 aberrant effect Effects 0.000 claims description 10
• 125000001309 chloro group Chemical group Cl* 0.000 claims description 10
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 10
• SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 9
• 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 9
• 125000002541 furyl group Chemical group 0.000 claims description 9
• 150000004677 hydrates Chemical class 0.000 claims description 9
• 238000004519 manufacturing process Methods 0.000 claims description 9
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
• 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 claims description 8
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 8
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 8
• JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical compound C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 claims description 8
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 8
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 7
• 230000003205 diastolic effect Effects 0.000 claims description 7
• 125000000714 pyrimidinyl group Chemical group 0.000 claims description 7
• 201000001320 Atherosclerosis Diseases 0.000 claims description 6
• 208000008589 Obesity Diseases 0.000 claims description 6
• 201000004681 Psoriasis Diseases 0.000 claims description 6
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
• 235000020824 obesity Nutrition 0.000 claims description 6
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
• UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 6
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 6
• 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 6
• 230000008728 vascular permeability Effects 0.000 claims description 6
• 125000005960 1,4-diazepanyl group Chemical group 0.000 claims description 5
• 201000009030 Carcinoma Diseases 0.000 claims description 5
• 201000004404 Neurofibroma Diseases 0.000 claims description 5
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 5
• 125000004076 pyridyl group Chemical group 0.000 claims description 5
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 5
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
• 229930012538 Paclitaxel Natural products 0.000 claims description 4
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 4
• 229960000397 bevacizumab Drugs 0.000 claims description 4
• 229960001592 paclitaxel Drugs 0.000 claims description 4
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 4
• 125000001544 thienyl group Chemical group 0.000 claims description 4
• IGERFAHWSHDDHX-UHFFFAOYSA-N 1,3-dioxanyl Chemical group [CH]1OCCCO1 IGERFAHWSHDDHX-UHFFFAOYSA-N 0.000 claims description 3
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
• 208000006168 Ewing Sarcoma Diseases 0.000 claims description 3
• GDYMJVNCHJZFAJ-UHFFFAOYSA-N N1C2=CC=CC=C2C2=C1CN(C(=O)O)C=C2 Chemical compound N1C2=CC=CC=C2C2=C1CN(C(=O)O)C=C2 GDYMJVNCHJZFAJ-UHFFFAOYSA-N 0.000 claims description 3
• 206010029260 Neuroblastoma Diseases 0.000 claims description 3
• 208000008383 Wilms tumor Diseases 0.000 claims description 3
• 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 claims description 3
• 210000002615 epidermis Anatomy 0.000 claims description 3
• 201000001441 melanoma Diseases 0.000 claims description 3
• 201000008026 nephroblastoma Diseases 0.000 claims description 3
• 125000000160 oxazolidinyl group Chemical group 0.000 claims description 3
• 125000000466 oxiranyl group Chemical group 0.000 claims description 3
• 230000002085 persistent effect Effects 0.000 claims description 3
• 125000003373 pyrazinyl group Chemical group 0.000 claims description 3
• 125000003226 pyrazolyl group Chemical group 0.000 claims description 3
• 230000000306 recurrent effect Effects 0.000 claims description 3
• 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 3
• 125000001425 triazolyl group Chemical group 0.000 claims description 3
• 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims description 3
• UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims description 3
• 229960000241 vandetanib Drugs 0.000 claims description 3
• 229950000578 vatalanib Drugs 0.000 claims description 3
• YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 claims description 3
• GTXSRFUZSLTDFX-HRCADAONSA-N (2s)-n-[(2s)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-4-methyl-2-[[(2s)-2-sulfanyl-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)butanoyl]amino]pentanamide Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O GTXSRFUZSLTDFX-HRCADAONSA-N 0.000 claims description 2
• SRSHBZRURUNOSM-UHFFFAOYSA-N (4-chlorophenyl) 6-chloro-1-(4-methoxyphenyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate Chemical compound C1=CC(OC)=CC=C1C1C(NC=2C3=CC(Cl)=CC=2)=C3CCN1C(=O)OC1=CC=C(Cl)C=C1 SRSHBZRURUNOSM-UHFFFAOYSA-N 0.000 claims description 2
• OKICBBUCPBAIMX-UHFFFAOYSA-N (4-chlorophenyl) 6-chloro-1-[4-[2-(pyridin-3-ylamino)ethoxy]phenyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate Chemical compound C1=CC(Cl)=CC=C1OC(=O)N1C(C=2C=CC(OCCNC=3C=NC=CC=3)=CC=2)C(NC=2C3=CC(Cl)=CC=2)=C3CC1 OKICBBUCPBAIMX-UHFFFAOYSA-N 0.000 claims description 2
• YCGZXOVOFUPVNR-UHFFFAOYSA-N (4-methylphenyl) 6-chloro-1-(4-methoxyphenyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate Chemical compound C1=CC(OC)=CC=C1C1C(NC=2C3=CC(Cl)=CC=2)=C3CCN1C(=O)OC1=CC=C(C)C=C1 YCGZXOVOFUPVNR-UHFFFAOYSA-N 0.000 claims description 2
• BHODKHQTWZACHM-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-yl)-6-chloro-2-pyrimidin-2-yl-1,3,4,9-tetrahydropyrido[3,4-b]indole Chemical compound C1CC=2C3=CC(Cl)=CC=C3NC=2C(C=2C=C3OCOC3=CC=2)N1C1=NC=CC=N1 BHODKHQTWZACHM-UHFFFAOYSA-N 0.000 claims description 2
• UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims description 2
• NUJNBJAZHPHBAI-UHFFFAOYSA-N 2-chloroethyl 6-chloro-1-(4-cyanophenyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate Chemical compound ClCCOC(=O)N1CCC(C2=CC(Cl)=CC=C2N2)=C2C1C1=CC=C(C#N)C=C1 NUJNBJAZHPHBAI-UHFFFAOYSA-N 0.000 claims description 2
• CQOQDQWUFQDJMK-SSTWWWIQSA-N 2-methoxy-17beta-estradiol Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 CQOQDQWUFQDJMK-SSTWWWIQSA-N 0.000 claims description 2
• NHFDRBXTEDBWCZ-ZROIWOOFSA-N 3-[2,4-dimethyl-5-[(z)-(2-oxo-1h-indol-3-ylidene)methyl]-1h-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=C(C)NC(\C=C/2C3=CC=CC=C3NC\2=O)=C1C NHFDRBXTEDBWCZ-ZROIWOOFSA-N 0.000 claims description 2
• 125000001819 4H-chromenyl group Chemical group O1C(=CCC2=CC=CC=C12)* 0.000 claims description 2
• LPZCGOSGZBRKHQ-UHFFFAOYSA-N 6-bromo-1-(4-chlorophenyl)-2-hydroxy-1,3,4,9-tetrahydropyrido[3,4-b]indole Chemical compound ON1CCC(C2=CC(Br)=CC=C2N2)=C2C1C1=CC=C(Cl)C=C1 LPZCGOSGZBRKHQ-UHFFFAOYSA-N 0.000 claims description 2
• KIDPWNPXFFHEAY-UHFFFAOYSA-N 6-bromo-1-(4-propan-2-ylphenyl)-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole Chemical compound C1=CC(C(C)C)=CC=C1C1C(NC=2C3=CC(Br)=CC=2)=C3CCN1 KIDPWNPXFFHEAY-UHFFFAOYSA-N 0.000 claims description 2
• IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims description 2
• 102400000068 Angiostatin Human genes 0.000 claims description 2
• 108010079709 Angiostatins Proteins 0.000 claims description 2
• BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims description 2
• 201000011057 Breast sarcoma Diseases 0.000 claims description 2
• 206010009944 Colon cancer Diseases 0.000 claims description 2
• 108010079505 Endostatins Proteins 0.000 claims description 2
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 2
• 102000006992 Interferon-alpha Human genes 0.000 claims description 2
• 108010047761 Interferon-alpha Proteins 0.000 claims description 2
• 102000013462 Interleukin-12 Human genes 0.000 claims description 2
• 108010065805 Interleukin-12 Proteins 0.000 claims description 2
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
• 206010038389 Renal cancer Diseases 0.000 claims description 2
• 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
• UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 claims description 2
• UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 claims description 2
• 229940087620 aromasin Drugs 0.000 claims description 2
• FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 claims description 2
• 210000000481 breast Anatomy 0.000 claims description 2
• WNRZHQBJSXRYJK-UHFFFAOYSA-N carboxyamidotriazole Chemical compound NC1=C(C(=O)N)N=NN1CC(C=C1Cl)=CC(Cl)=C1C(=O)C1=CC=C(Cl)C=C1 WNRZHQBJSXRYJK-UHFFFAOYSA-N 0.000 claims description 2
• RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims description 2
• 229960000590 celecoxib Drugs 0.000 claims description 2
• 208000019065 cervical carcinoma Diseases 0.000 claims description 2
• ZXFCRFYULUUSDW-OWXODZSWSA-N chembl2104970 Chemical compound C([C@H]1C2)C3=CC=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2CC(O)=C(C(=O)N)C1=O ZXFCRFYULUUSDW-OWXODZSWSA-N 0.000 claims description 2
• 229950009003 cilengitide Drugs 0.000 claims description 2
• AMLYAMJWYAIXIA-VWNVYAMZSA-N cilengitide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)N(C)C(=O)[C@H]1CC1=CC=CC=C1 AMLYAMJWYAIXIA-VWNVYAMZSA-N 0.000 claims description 2
• WDOGQTQEKVLZIJ-WAYWQWQTSA-N combretastatin a-4 phosphate Chemical compound C1=C(OP(O)(O)=O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 WDOGQTQEKVLZIJ-WAYWQWQTSA-N 0.000 claims description 2
• 229940111134 coxibs Drugs 0.000 claims description 2
• 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 2
• 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims description 2
• 229960004679 doxorubicin Drugs 0.000 claims description 2
• TXFKYMRGYMFTHU-UHFFFAOYSA-N ethyl 6-bromo-1-(4-chlorophenyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate Chemical compound CCOC(=O)N1CCC(C2=CC(Br)=CC=C2N2)=C2C1C1=CC=C(Cl)C=C1 TXFKYMRGYMFTHU-UHFFFAOYSA-N 0.000 claims description 2
• GQUICLCJNAEHGT-UHFFFAOYSA-N ethyl 6-bromo-1-(4-methylphenyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate Chemical compound CCOC(=O)N1CCC(C2=CC(Br)=CC=C2N2)=C2C1C1=CC=C(C)C=C1 GQUICLCJNAEHGT-UHFFFAOYSA-N 0.000 claims description 2
• LLWYMMOYIXVXHY-UHFFFAOYSA-N ethyl 6-bromo-1-(4-propan-2-ylphenyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate Chemical compound CCOC(=O)N1CCC(C2=CC(Br)=CC=C2N2)=C2C1C1=CC=C(C(C)C)C=C1 LLWYMMOYIXVXHY-UHFFFAOYSA-N 0.000 claims description 2
• SVXKJLUCDKIRAY-UHFFFAOYSA-N ethyl 6-chloro-1-(2,3-difluorophenyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate Chemical compound CCOC(=O)N1CCC(C2=CC(Cl)=CC=C2N2)=C2C1C1=CC=CC(F)=C1F SVXKJLUCDKIRAY-UHFFFAOYSA-N 0.000 claims description 2
• STYIGPYZNXSTNQ-UHFFFAOYSA-N ethyl 6-chloro-1-(4-chlorophenyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate Chemical compound CCOC(=O)N1CCC(C2=CC(Cl)=CC=C2N2)=C2C1C1=CC=C(Cl)C=C1 STYIGPYZNXSTNQ-UHFFFAOYSA-N 0.000 claims description 2
• DBGASQGSTUZRKN-UHFFFAOYSA-N ethyl 6-chloro-1-(4-fluorophenyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate Chemical compound CCOC(=O)N1CCC(C2=CC(Cl)=CC=C2N2)=C2C1C1=CC=C(F)C=C1 DBGASQGSTUZRKN-UHFFFAOYSA-N 0.000 claims description 2
• BVQAGLQMGXGGNS-UHFFFAOYSA-N ethyl 6-chloro-1-(4-methoxyphenyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate Chemical compound CCOC(=O)N1CCC(C2=CC(Cl)=CC=C2N2)=C2C1C1=CC=C(OC)C=C1 BVQAGLQMGXGGNS-UHFFFAOYSA-N 0.000 claims description 2
• 229960002949 fluorouracil Drugs 0.000 claims description 2
• 229960005277 gemcitabine Drugs 0.000 claims description 2
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 2
• LVASCWIMLIKXLA-LSDHHAIUSA-N halofuginone Chemical compound O[C@@H]1CCCN[C@H]1CC(=O)CN1C(=O)C2=CC(Cl)=C(Br)C=C2N=C1 LVASCWIMLIKXLA-LSDHHAIUSA-N 0.000 claims description 2
• 229950010152 halofuginone Drugs 0.000 claims description 2
• 229940117681 interleukin-12 Drugs 0.000 claims description 2
• 229960004942 lenalidomide Drugs 0.000 claims description 2
• GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims description 2
• 201000005296 lung carcinoma Diseases 0.000 claims description 2
• 201000010174 renal carcinoma Diseases 0.000 claims description 2
• 229950001248 squalamine Drugs 0.000 claims description 2
• 229960001603 tamoxifen Drugs 0.000 claims description 2
• 229960003433 thalidomide Drugs 0.000 claims description 2
• 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 3
• RERZNCLIYCABFS-UHFFFAOYSA-N harmaline Chemical compound C1CN=C(C)C2=C1C1=CC=C(OC)C=C1N2 RERZNCLIYCABFS-UHFFFAOYSA-N 0.000 claims 3
• 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 2
• WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 claims 1
• 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims 1
• 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 claims 1
• 229940125898 compound 5 Drugs 0.000 claims 1
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
• 229960002633 ramucirumab Drugs 0.000 claims 1
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 164
• 238000000034 method Methods 0.000 description 73
• 230000000694 effects Effects 0.000 description 30
• 125000003282 alkyl amino group Chemical group 0.000 description 28
• 229910052757 nitrogen Inorganic materials 0.000 description 25
• 125000003545 alkoxy group Chemical group 0.000 description 21
• 241000699666 Mus <mouse, genus> Species 0.000 description 17
• 241000699670 Mus sp. Species 0.000 description 16
• 210000004027 cell Anatomy 0.000 description 16
• 239000000523 sample Substances 0.000 description 14
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 12
• 108091008605 VEGF receptors Proteins 0.000 description 12
• 230000005764 inhibitory process Effects 0.000 description 12
• 150000003254 radicals Chemical class 0.000 description 12
• 241000282414 Homo sapiens Species 0.000 description 11
• 210000004369 blood Anatomy 0.000 description 11
• 239000008280 blood Substances 0.000 description 11
• 235000012054 meals Nutrition 0.000 description 11
• 239000000725 suspension Substances 0.000 description 11
• 239000004480 active ingredient Substances 0.000 description 10
• 125000004414 alkyl thio group Chemical group 0.000 description 10
• 238000012360 testing method Methods 0.000 description 10
• 208000006011 Stroke Diseases 0.000 description 9
• 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 9
• 230000004614 tumor growth Effects 0.000 description 9
• 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 8
• 229920000858 Cyclodextrin Polymers 0.000 description 8
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
• 206010021143 Hypoxia Diseases 0.000 description 8
• 238000003556 assay Methods 0.000 description 8
• 229910052760 oxygen Inorganic materials 0.000 description 8
• 230000001225 therapeutic effect Effects 0.000 description 8
• 239000003981 vehicle Substances 0.000 description 8
• 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 7
• 208000005623 Carcinogenesis Diseases 0.000 description 7
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 7
• 230000036952 cancer formation Effects 0.000 description 7
• 231100000504 carcinogenesis Toxicity 0.000 description 7
• 239000000839 emulsion Substances 0.000 description 7
• 238000002360 preparation method Methods 0.000 description 7
• 210000002966 serum Anatomy 0.000 description 7
• 230000002792 vascular Effects 0.000 description 7
• 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 6
• 125000004390 alkyl sulfonyl group Chemical group 0.000 description 6
• 125000002619 bicyclic group Chemical group 0.000 description 6
• 125000004432 carbon atom Chemical group C* 0.000 description 6
• 230000000875 corresponding effect Effects 0.000 description 6
• 235000014113 dietary fatty acids Nutrition 0.000 description 6
• 239000000194 fatty acid Substances 0.000 description 6
• 229930195729 fatty acid Natural products 0.000 description 6
• 150000004665 fatty acids Chemical class 0.000 description 6
• 125000002950 monocyclic group Chemical group 0.000 description 6
• 102000005962 receptors Human genes 0.000 description 6
• 108020003175 receptors Proteins 0.000 description 6
• 239000002904 solvent Substances 0.000 description 6
• 239000003826 tablet Substances 0.000 description 6
• GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 description 6
• 230000005747 tumor angiogenesis Effects 0.000 description 6
• 108010007859 Lisinopril Proteins 0.000 description 5
• 241000699660 Mus musculus Species 0.000 description 5
• 206010029113 Neovascularisation Diseases 0.000 description 5
• 108020004459 Small interfering RNA Proteins 0.000 description 5
• 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 5
• 238000013459 approach Methods 0.000 description 5
• 238000011161 development Methods 0.000 description 5
• 230000018109 developmental process Effects 0.000 description 5
• 238000002474 experimental method Methods 0.000 description 5
• 235000013305 food Nutrition 0.000 description 5
• 230000012010 growth Effects 0.000 description 5
• 239000003102 growth factor Substances 0.000 description 5
• 238000001727 in vivo Methods 0.000 description 5
• 230000000670 limiting effect Effects 0.000 description 5
• CZRQXSDBMCMPNJ-ZUIPZQNBSA-N lisinopril dihydrate Chemical compound O.O.C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 CZRQXSDBMCMPNJ-ZUIPZQNBSA-N 0.000 description 5
• 230000036961 partial effect Effects 0.000 description 5
• 239000000047 product Substances 0.000 description 5
• 238000002560 therapeutic procedure Methods 0.000 description 5
• ULQISTXYYBZJSJ-UHFFFAOYSA-N 12-hydroxyoctadecanoic acid Chemical compound CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 description 4
• JVKUCNQGESRUCL-UHFFFAOYSA-N 2-Hydroxyethyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCCO JVKUCNQGESRUCL-UHFFFAOYSA-N 0.000 description 4
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
• 206010019233 Headaches Diseases 0.000 description 4
• 206010028813 Nausea Diseases 0.000 description 4
• 206010039491 Sarcoma Diseases 0.000 description 4
• 229920001304 Solutol HS 15 Polymers 0.000 description 4
• MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical class [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 4
• 238000004458 analytical method Methods 0.000 description 4
• 238000010171 animal model Methods 0.000 description 4
• 230000037396 body weight Effects 0.000 description 4
• 239000002775 capsule Substances 0.000 description 4
• 230000010261 cell growth Effects 0.000 description 4
• 239000007859 condensation product Substances 0.000 description 4
• 230000002596 correlated effect Effects 0.000 description 4
• 230000003247 decreasing effect Effects 0.000 description 4
• 208000037765 diseases and disorders Diseases 0.000 description 4
• 239000002552 dosage form Substances 0.000 description 4
• 229940079593 drug Drugs 0.000 description 4
• 238000007876 drug discovery Methods 0.000 description 4
• 235000003599 food sweetener Nutrition 0.000 description 4
• 239000007903 gelatin capsule Substances 0.000 description 4
• 231100000869 headache Toxicity 0.000 description 4
• 230000007954 hypoxia Effects 0.000 description 4
• 238000004811 liquid chromatography Methods 0.000 description 4
• 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 4
• 239000002207 metabolite Substances 0.000 description 4
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
• 230000008693 nausea Effects 0.000 description 4
• 238000011580 nude mouse model Methods 0.000 description 4
• 239000000843 powder Substances 0.000 description 4
• 230000002829 reductive effect Effects 0.000 description 4
• 230000002207 retinal effect Effects 0.000 description 4
• 239000007787 solid Substances 0.000 description 4
• 239000000243 solution Substances 0.000 description 4
• 239000003765 sweetening agent Substances 0.000 description 4
• 238000004885 tandem mass spectrometry Methods 0.000 description 4
• 210000001519 tissue Anatomy 0.000 description 4
• 231100000419 toxicity Toxicity 0.000 description 4
• 230000001988 toxicity Effects 0.000 description 4
• 230000006711 vascular endothelial growth factor production Effects 0.000 description 4
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
• 108020005345 3' Untranslated Regions Proteins 0.000 description 3
• 108020003589 5' Untranslated Regions Proteins 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• 208000005590 Choroidal Neovascularization Diseases 0.000 description 3
• 206010060823 Choroidal neovascularisation Diseases 0.000 description 3
• 108090000695 Cytokines Proteins 0.000 description 3
• 102000004127 Cytokines Human genes 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
• 201000008808 Fibrosarcoma Diseases 0.000 description 3
• 241001465754 Metazoa Species 0.000 description 3
• 241000700159 Rattus Species 0.000 description 3
• 208000007135 Retinal Neovascularization Diseases 0.000 description 3
• 206010047700 Vomiting Diseases 0.000 description 3
• 239000002870 angiogenesis inducing agent Substances 0.000 description 3
• 239000003963 antioxidant agent Substances 0.000 description 3
• 235000006708 antioxidants Nutrition 0.000 description 3
• 150000001721 carbon Chemical group 0.000 description 3
• 238000004113 cell culture Methods 0.000 description 3
• 230000004663 cell proliferation Effects 0.000 description 3
• 239000003086 colorant Substances 0.000 description 3
• 238000002648 combination therapy Methods 0.000 description 3
• 230000007423 decrease Effects 0.000 description 3
• 239000003085 diluting agent Substances 0.000 description 3
• 208000002173 dizziness Diseases 0.000 description 3
• 210000002889 endothelial cell Anatomy 0.000 description 3
• 239000000796 flavoring agent Substances 0.000 description 3
• 235000013355 food flavoring agent Nutrition 0.000 description 3
• 235000011187 glycerol Nutrition 0.000 description 3
• 230000001146 hypoxic effect Effects 0.000 description 3
• 239000003112 inhibitor Substances 0.000 description 3
• 150000004667 medium chain fatty acids Chemical class 0.000 description 3
• 239000003921 oil Substances 0.000 description 3
• 235000019198 oils Nutrition 0.000 description 3
• 230000008506 pathogenesis Effects 0.000 description 3
• 239000008177 pharmaceutical agent Substances 0.000 description 3
• 125000003367 polycyclic group Chemical group 0.000 description 3
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
• 239000003755 preservative agent Substances 0.000 description 3
• 230000001023 pro-angiogenic effect Effects 0.000 description 3
• 230000008569 process Effects 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 230000001105 regulatory effect Effects 0.000 description 3
• 230000019491 signal transduction Effects 0.000 description 3
• 230000011664 signaling Effects 0.000 description 3
• 239000011734 sodium Substances 0.000 description 3
• 239000008137 solubility enhancer Substances 0.000 description 3
• 229910052717 sulfur Inorganic materials 0.000 description 3
• 239000006188 syrup Substances 0.000 description 3
• 235000020357 syrup Nutrition 0.000 description 3
• 230000014621 translational initiation Effects 0.000 description 3
• 238000005353 urine analysis Methods 0.000 description 3
• 230000007998 vessel formation Effects 0.000 description 3
• 230000008673 vomiting Effects 0.000 description 3
• 239000000080 wetting agent Substances 0.000 description 3
• DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
• 229940114072 12-hydroxystearic acid Drugs 0.000 description 2
• IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
• 239000005541 ACE inhibitor Substances 0.000 description 2
• 244000215068 Acacia senegal Species 0.000 description 2
• 235000006491 Acacia senegal Nutrition 0.000 description 2
• 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 2
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
• 102000008873 Angiotensin II receptor Human genes 0.000 description 2
• 108050000824 Angiotensin II receptor Proteins 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 241000416162 Astragalus gummifer Species 0.000 description 2
• 239000002083 C09CA01 - Losartan Substances 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• 108090000994 Catalytic RNA Proteins 0.000 description 2
• 102000053642 Catalytic RNA Human genes 0.000 description 2
• 206010011906 Death Diseases 0.000 description 2
• 206010012735 Diarrhoea Diseases 0.000 description 2
• 238000002965 ELISA Methods 0.000 description 2
• 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
• 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
• XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 2
• 229920000084 Gum arabic Polymers 0.000 description 2
• 208000032843 Hemorrhage Diseases 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• 101000919395 Homo sapiens Aromatase Proteins 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• 241001529936 Murinae Species 0.000 description 2
• WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
• 206010061309 Neoplasm progression Diseases 0.000 description 2
• 108091034117 Oligonucleotide Proteins 0.000 description 2
• 108700020796 Oncogene Proteins 0.000 description 2
• 108010029485 Protein Isoforms Proteins 0.000 description 2
• 102000001708 Protein Isoforms Human genes 0.000 description 2
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• 235000021355 Stearic acid Nutrition 0.000 description 2
• 238000000692 Student's t-test Methods 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• 229920001615 Tragacanth Polymers 0.000 description 2
• 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 2
• 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 2
• 206010000059 abdominal discomfort Diseases 0.000 description 2
• 235000010489 acacia gum Nutrition 0.000 description 2
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
• 239000013543 active substance Substances 0.000 description 2
• 238000007792 addition Methods 0.000 description 2
• 206010064930 age-related macular degeneration Diseases 0.000 description 2
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
• 230000000692 anti-sense effect Effects 0.000 description 2
• 230000003078 antioxidant effect Effects 0.000 description 2
• 125000004429 atom Chemical group 0.000 description 2
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
• 230000004888 barrier function Effects 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• 125000001246 bromo group Chemical group Br* 0.000 description 2
• 239000001506 calcium phosphate Substances 0.000 description 2
• 229910000389 calcium phosphate Inorganic materials 0.000 description 2
• 235000011010 calcium phosphates Nutrition 0.000 description 2
• 150000001720 carbohydrates Chemical class 0.000 description 2
• 235000014633 carbohydrates Nutrition 0.000 description 2
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
• 239000003183 carcinogenic agent Substances 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 235000010980 cellulose Nutrition 0.000 description 2
• 238000006243 chemical reaction Methods 0.000 description 2
• 238000011284 combination treatment Methods 0.000 description 2
• 239000012084 conversion product Substances 0.000 description 2
• 230000036757 core body temperature Effects 0.000 description 2
• 229940097362 cyclodextrins Drugs 0.000 description 2
• 231100000135 cytotoxicity Toxicity 0.000 description 2
• 230000003013 cytotoxicity Effects 0.000 description 2
• 239000002270 dispersing agent Substances 0.000 description 2
• 239000003995 emulsifying agent Substances 0.000 description 2
• 230000032050 esterification Effects 0.000 description 2
• 238000005886 esterification reaction Methods 0.000 description 2
• 125000001153 fluoro group Chemical group F* 0.000 description 2
• 230000009246 food effect Effects 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 125000005842 heteroatom Chemical group 0.000 description 2
• BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
• 238000000338 in vitro Methods 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• 230000002601 intratumoral effect Effects 0.000 description 2
• 125000002346 iodo group Chemical group I* 0.000 description 2
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 239000007788 liquid Substances 0.000 description 2
• 229940057995 liquid paraffin Drugs 0.000 description 2
• 229960002394 lisinopril Drugs 0.000 description 2
• KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 2
• 229960004773 losartan Drugs 0.000 description 2
• 229920002521 macromolecule Polymers 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 238000005259 measurement Methods 0.000 description 2
• 230000002503 metabolic effect Effects 0.000 description 2
• 239000004530 micro-emulsion Substances 0.000 description 2
• 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
• 230000035772 mutation Effects 0.000 description 2
• 230000014399 negative regulation of angiogenesis Effects 0.000 description 2
• 125000004433 nitrogen atom Chemical group N* 0.000 description 2
• 239000000346 nonvolatile oil Substances 0.000 description 2
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
• WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
• 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 239000004006 olive oil Substances 0.000 description 2
• 235000008390 olive oil Nutrition 0.000 description 2
• 239000001301 oxygen Substances 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
• 229920000053 polysorbate 80 Polymers 0.000 description 2
• 230000001124 posttranscriptional effect Effects 0.000 description 2
• 229940069328 povidone Drugs 0.000 description 2
• 230000000069 prophylactic effect Effects 0.000 description 2
• 229960004063 propylene glycol Drugs 0.000 description 2
• 235000013772 propylene glycol Nutrition 0.000 description 2
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
• 210000002307 prostate Anatomy 0.000 description 2
• 230000002685 pulmonary effect Effects 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 108091092562 ribozyme Proteins 0.000 description 2
• 229920006395 saturated elastomer Polymers 0.000 description 2
• HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
• 230000035945 sensitivity Effects 0.000 description 2
• 239000008117 stearic acid Substances 0.000 description 2
• 239000003270 steroid hormone Substances 0.000 description 2
• 239000000126 substance Substances 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 125000004434 sulfur atom Chemical group 0.000 description 2
• 239000000375 suspending agent Substances 0.000 description 2
• 230000008685 targeting Effects 0.000 description 2
• 230000001052 transient effect Effects 0.000 description 2
• 210000004881 tumor cell Anatomy 0.000 description 2
• 230000005751 tumor progression Effects 0.000 description 2
• 229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
• 235000015112 vegetable and seed oil Nutrition 0.000 description 2
• 239000008158 vegetable oil Substances 0.000 description 2
• 229940072252 zestril Drugs 0.000 description 2
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
• LTYCLHYFTILWIO-UHFFFAOYSA-N (4-chlorophenyl) 6-bromo-1-(4-methoxyphenyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate Chemical compound C1=CC(OC)=CC=C1C1C(NC=2C3=CC(Br)=CC=2)=C3CCN1C(=O)OC1=CC=C(Cl)C=C1 LTYCLHYFTILWIO-UHFFFAOYSA-N 0.000 description 1
• XUBZRVSRVDSYAG-UHFFFAOYSA-N (4-chlorophenyl) 6-chloro-1-[4-(2-morpholin-4-ylethoxy)phenyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate Chemical compound C1=CC(Cl)=CC=C1OC(=O)N1C(C=2C=CC(OCCN3CCOCC3)=CC=2)C(NC=2C3=CC(Cl)=CC=2)=C3CC1 XUBZRVSRVDSYAG-UHFFFAOYSA-N 0.000 description 1
• DUDDJNQIIWSKFH-UHFFFAOYSA-N (4-chlorophenyl) 6-chloro-1-[4-[2-(1,3-thiazol-2-ylamino)ethoxy]phenyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate Chemical compound C1=CC(Cl)=CC=C1OC(=O)N1C(C=2C=CC(OCCNC=3SC=CN=3)=CC=2)C(NC=2C3=CC(Cl)=CC=2)=C3CC1 DUDDJNQIIWSKFH-UHFFFAOYSA-N 0.000 description 1
• CJLKDYPSWBNEOU-UHFFFAOYSA-N (4-chlorophenyl) 6-chloro-1-[4-[2-[(5-methyl-1,3-thiazol-2-yl)amino]ethoxy]phenyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate Chemical compound S1C(C)=CN=C1NCCOC1=CC=C(C2C3=C(C4=CC(Cl)=CC=C4N3)CCN2C(=O)OC=2C=CC(Cl)=CC=2)C=C1 CJLKDYPSWBNEOU-UHFFFAOYSA-N 0.000 description 1
• JFBBWBSGQCPSTK-UHFFFAOYSA-N (4-fluorophenyl) 6-chloro-1-[4-[2-(1,3-thiazol-2-ylamino)ethoxy]phenyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate Chemical compound C1=CC(F)=CC=C1OC(=O)N1C(C=2C=CC(OCCNC=3SC=CN=3)=CC=2)C(NC=2C3=CC(Cl)=CC=2)=C3CC1 JFBBWBSGQCPSTK-UHFFFAOYSA-N 0.000 description 1
• BYGDKDOAGJMURK-UHFFFAOYSA-N (4-fluorophenyl) 6-chloro-1-[4-[2-[(5-methyl-1,3-thiazol-2-yl)amino]ethoxy]phenyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate Chemical compound S1C(C)=CN=C1NCCOC1=CC=C(C2C3=C(C4=CC(Cl)=CC=C4N3)CCN2C(=O)OC=2C=CC(F)=CC=2)C=C1 BYGDKDOAGJMURK-UHFFFAOYSA-N 0.000 description 1
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
• ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
• 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
• BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 1
• JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
• VMJNTFXCTXAXTC-UHFFFAOYSA-N 2,2-difluoro-1,3-benzodioxole-5-carbonitrile Chemical group C1=C(C#N)C=C2OC(F)(F)OC2=C1 VMJNTFXCTXAXTC-UHFFFAOYSA-N 0.000 description 1
• FRUWMYWEARDNTC-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1h-indole Chemical compound C1C=CC=C2NCCC21 FRUWMYWEARDNTC-UHFFFAOYSA-N 0.000 description 1
• YPJJJQIMVJZMDE-UHFFFAOYSA-N 2-fluoroethyl 6-chloro-1-(4-propan-2-ylphenyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate Chemical compound C1=CC(C(C)C)=CC=C1C1C(NC=2C3=CC(Cl)=CC=2)=C3CCN1C(=O)OCCF YPJJJQIMVJZMDE-UHFFFAOYSA-N 0.000 description 1
• SKLKCBRXTBRVKS-UHFFFAOYSA-N 2-methoxyethyl 6-chloro-1-[4-[2-(1,3-thiazol-2-ylamino)ethoxy]phenyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate Chemical compound COCCOC(=O)N1CCC(C2=CC(Cl)=CC=C2N2)=C2C1C(C=C1)=CC=C1OCCNC1=NC=CS1 SKLKCBRXTBRVKS-UHFFFAOYSA-N 0.000 description 1
• YEQRQCVRSFBXQP-UHFFFAOYSA-N 2-methoxyethyl 6-chloro-1-[4-[2-(pyridin-4-ylamino)ethoxy]phenyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate Chemical compound COCCOC(=O)N1CCC(C2=CC(Cl)=CC=C2N2)=C2C1C(C=C1)=CC=C1OCCNC1=CC=NC=C1 YEQRQCVRSFBXQP-UHFFFAOYSA-N 0.000 description 1
• YCSKVBAAYBUYLY-UHFFFAOYSA-N 2-methoxyethyl 6-chloro-1-[4-[2-[(5-methyl-1,3-thiazol-2-yl)amino]ethoxy]phenyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate Chemical compound COCCOC(=O)N1CCC(C2=CC(Cl)=CC=C2N2)=C2C1C(C=C1)=CC=C1OCCNC1=NC=C(C)S1 YCSKVBAAYBUYLY-UHFFFAOYSA-N 0.000 description 1
• BILJHYHHBJGJNT-UHFFFAOYSA-N 2-methylpropyl 6-chloro-1-[4-[2-(1,3-thiazol-2-ylamino)ethoxy]phenyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate Chemical compound CC(C)COC(=O)N1CCC(C2=CC(Cl)=CC=C2N2)=C2C1C(C=C1)=CC=C1OCCNC1=NC=CS1 BILJHYHHBJGJNT-UHFFFAOYSA-N 0.000 description 1
• GIJLRSTVBFAMMF-UHFFFAOYSA-N 2-methylpropyl 6-chloro-1-[4-[2-(pyridin-4-ylamino)ethoxy]phenyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate Chemical compound CC(C)COC(=O)N1CCC(C2=CC(Cl)=CC=C2N2)=C2C1C(C=C1)=CC=C1OCCNC1=CC=NC=C1 GIJLRSTVBFAMMF-UHFFFAOYSA-N 0.000 description 1
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
• 125000000850 2H-chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
• VOJNALBKRSHELT-UHFFFAOYSA-N 6-bromo-1-(3-chlorophenyl)-n-cyclohexyl-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxamide Chemical compound ClC1=CC=CC(C2C3=C(C4=CC(Br)=CC=C4N3)CCN2C(=O)NC2CCCCC2)=C1 VOJNALBKRSHELT-UHFFFAOYSA-N 0.000 description 1
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
• NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
• 206010067484 Adverse reaction Diseases 0.000 description 1
• 239000005995 Aluminium silicate Substances 0.000 description 1
• 231100000039 Ames test Toxicity 0.000 description 1
• 108091023037 Aptamer Proteins 0.000 description 1
• 235000003911 Arachis Nutrition 0.000 description 1
• 244000105624 Arachis hypogaea Species 0.000 description 1
• 229940122815 Aromatase inhibitor Drugs 0.000 description 1
• 206010003571 Astrocytoma Diseases 0.000 description 1
• 206010003591 Ataxia Diseases 0.000 description 1
• 208000008035 Back Pain Diseases 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• 201000004569 Blindness Diseases 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
• GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
• 229940127291 Calcium channel antagonist Drugs 0.000 description 1
• 241000282465 Canis Species 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 239000004215 Carbon black (E152) Substances 0.000 description 1
• 208000009458 Carcinoma in Situ Diseases 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 206010008342 Cervix carcinoma Diseases 0.000 description 1
• 208000031404 Chromosome Aberrations Diseases 0.000 description 1
• 206010053567 Coagulopathies Diseases 0.000 description 1
• 206010010774 Constipation Diseases 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 229920002785 Croscarmellose sodium Polymers 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 230000005778 DNA damage Effects 0.000 description 1
• 231100000277 DNA damage Toxicity 0.000 description 1
• 229920001353 Dextrin Polymers 0.000 description 1
• 239000004375 Dextrin Substances 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 102400001047 Endostatin Human genes 0.000 description 1
• 208000010201 Exanthema Diseases 0.000 description 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
• 206010052140 Eye pruritus Diseases 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 206010018338 Glioma Diseases 0.000 description 1
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
• 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
• 206010019280 Heart failures Diseases 0.000 description 1
• 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 description 1
• 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
• 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
• 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 1
• 208000008839 Kidney Neoplasms Diseases 0.000 description 1
• 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
• 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• 235000019759 Maize starch Nutrition 0.000 description 1
• QPJVMBTYPHYUOC-UHFFFAOYSA-N Methyl benzoate Natural products COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 1
• 238000005481 NMR spectroscopy Methods 0.000 description 1
• SSURCGGGQUWIHH-UHFFFAOYSA-N NNON Chemical compound NNON SSURCGGGQUWIHH-UHFFFAOYSA-N 0.000 description 1
• 206010029164 Nephrotic syndrome Diseases 0.000 description 1
• 102000002111 Neuropilin Human genes 0.000 description 1
• 108050009450 Neuropilin Proteins 0.000 description 1
• 208000022873 Ocular disease Diseases 0.000 description 1
• 239000005642 Oleic acid Substances 0.000 description 1
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
• 102000043276 Oncogene Human genes 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 101000831256 Oryza sativa subsp. japonica Cysteine proteinase inhibitor 1 Proteins 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
• 208000020584 Polyploidy Diseases 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 206010036790 Productive cough Diseases 0.000 description 1
• 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
• 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
• 108091027981 Response element Proteins 0.000 description 1
• 206010038848 Retinal detachment Diseases 0.000 description 1
• 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
• 241000253387 Rhodobiaceae Species 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
• 229920002125 Sokalan® Polymers 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• 108091036066 Three prime untranslated region Proteins 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 102000009618 Transforming Growth Factors Human genes 0.000 description 1
• 108010009583 Transforming Growth Factors Proteins 0.000 description 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
• 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
• 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• 108091023045 Untranslated Region Proteins 0.000 description 1
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
• 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 1
• 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
• 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
• 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 238000009098 adjuvant therapy Methods 0.000 description 1
• 230000006838 adverse reaction Effects 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 125000002947 alkylene group Chemical group 0.000 description 1
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
• 235000012211 aluminium silicate Nutrition 0.000 description 1
• 230000009435 amidation Effects 0.000 description 1
• 238000007112 amidation reaction Methods 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• 125000004103 aminoalkyl group Chemical group 0.000 description 1
• 239000003098 androgen Substances 0.000 description 1
• 229940030486 androgens Drugs 0.000 description 1
• AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 1
• 229960005471 androstenedione Drugs 0.000 description 1
• AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 1
• 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
• 230000003527 anti-angiogenesis Effects 0.000 description 1
• 230000001772 anti-angiogenic effect Effects 0.000 description 1
• 230000001093 anti-cancer Effects 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 239000007900 aqueous suspension Substances 0.000 description 1
• 239000003886 aromatase inhibitor Substances 0.000 description 1
• 230000004872 arterial blood pressure Effects 0.000 description 1
• 150000005840 aryl radicals Chemical group 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 1
• 238000011717 athymic nude mouse Methods 0.000 description 1
• 125000002393 azetidinyl group Chemical group 0.000 description 1
• 125000003828 azulenyl group Chemical group 0.000 description 1
• 235000013871 bee wax Nutrition 0.000 description 1
• 239000012166 beeswax Substances 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 239000002876 beta blocker Substances 0.000 description 1
• 229940097320 beta blocking agent Drugs 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 239000012472 biological sample Substances 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 208000034158 bleeding Diseases 0.000 description 1
• 230000000740 bleeding effect Effects 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
• VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Substances [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
• 229910000019 calcium carbonate Inorganic materials 0.000 description 1
• 239000000480 calcium channel blocker Substances 0.000 description 1
• 229960001631 carbomer Drugs 0.000 description 1
• KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 230000002612 cardiopulmonary effect Effects 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 210000003986 cell retinal photoreceptor Anatomy 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 201000010881 cervical cancer Diseases 0.000 description 1
• 229960000541 cetyl alcohol Drugs 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
• 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
• 231100000005 chromosome aberration Toxicity 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 230000003541 clastogenic effect Effects 0.000 description 1
• 230000035602 clotting Effects 0.000 description 1
• 230000015271 coagulation Effects 0.000 description 1
• 238000005345 coagulation Methods 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 229960001681 croscarmellose sodium Drugs 0.000 description 1
• 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
• QPJDMGCKMHUXFD-UHFFFAOYSA-N cyanogen chloride Chemical compound ClC#N QPJDMGCKMHUXFD-UHFFFAOYSA-N 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
• 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical class CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 235000019425 dextrin Nutrition 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 238000009792 diffusion process Methods 0.000 description 1
• 125000004582 dihydrobenzothienyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 description 1
• 125000005435 dihydrobenzoxazolyl group Chemical group O1C(NC2=C1C=CC=C2)* 0.000 description 1
• 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
• 125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 description 1
• 125000004611 dihydroisoindolyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
• 125000005045 dihydroisoquinolinyl group Chemical group C1(NC=CC2=CC=CC=C12)* 0.000 description 1
• 125000005051 dihydropyrazinyl group Chemical group N1(CC=NC=C1)* 0.000 description 1
• 125000005052 dihydropyrazolyl group Chemical group N1(NCC=C1)* 0.000 description 1
• 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
• 125000005053 dihydropyrimidinyl group Chemical group N1(CN=CC=C1)* 0.000 description 1
• 125000004609 dihydroquinazolinyl group Chemical group N1(CN=CC2=CC=CC=C12)* 0.000 description 1
• 125000005044 dihydroquinolinyl group Chemical group N1(CC=CC2=CC=CC=C12)* 0.000 description 1
• 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
• HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
• 229960004166 diltiazem Drugs 0.000 description 1
• 239000002934 diuretic Substances 0.000 description 1
• 229940030606 diuretics Drugs 0.000 description 1
• 239000000890 drug combination Substances 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 230000036267 drug metabolism Effects 0.000 description 1
• 210000001671 embryonic stem cell Anatomy 0.000 description 1
• 239000003974 emollient agent Substances 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• IGTCWZXYEHLYDW-UHFFFAOYSA-N ethyl 6-chloro-1-[4-[2-[(5-methyl-1,3-thiazol-2-yl)amino]ethoxy]phenyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate Chemical compound CCOC(=O)N1CCC(C2=CC(Cl)=CC=C2N2)=C2C1C(C=C1)=CC=C1OCCNC1=NC=C(C)S1 IGTCWZXYEHLYDW-UHFFFAOYSA-N 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 201000005884 exanthem Diseases 0.000 description 1
• 210000002744 extracellular matrix Anatomy 0.000 description 1
• 229940087476 femara Drugs 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
• 229940074045 glyceryl distearate Drugs 0.000 description 1
• 229940075507 glyceryl monostearate Drugs 0.000 description 1
• 230000013595 glycosylation Effects 0.000 description 1
• 238000006206 glycosylation reaction Methods 0.000 description 1
• 230000000004 hemodynamic effect Effects 0.000 description 1
• 102000044018 human CYP19A1 Human genes 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
• 230000001631 hypertensive effect Effects 0.000 description 1
• 208000003532 hypothyroidism Diseases 0.000 description 1
• 230000002989 hypothyroidism Effects 0.000 description 1
• 125000002632 imidazolidinyl group Chemical group 0.000 description 1
• 125000002636 imidazolinyl group Chemical group 0.000 description 1
• 208000026278 immune system disease Diseases 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 201000004933 in situ carcinoma Diseases 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
• 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
• LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical compound C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 1
• 239000003701 inert diluent Substances 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 229940102223 injectable solution Drugs 0.000 description 1
• 229940102213 injectable suspension Drugs 0.000 description 1
• 206010022437 insomnia Diseases 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 230000000302 ischemic effect Effects 0.000 description 1
• 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
• 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
• 125000005969 isothiazolinyl group Chemical group 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
• 125000003971 isoxazolinyl group Chemical group 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
• 150000002605 large molecules Chemical class 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 208000013433 lightheadedness Diseases 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 239000006193 liquid solution Substances 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 208000020816 lung neoplasm Diseases 0.000 description 1
• 239000008176 lyophilized powder Substances 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 210000004088 microvessel Anatomy 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 230000007886 mutagenicity Effects 0.000 description 1
• 231100000299 mutagenicity Toxicity 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 239000002105 nanoparticle Substances 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 210000005170 neoplastic cell Anatomy 0.000 description 1
• 208000029974 neurofibrosarcoma Diseases 0.000 description 1
• 238000006386 neutralization reaction Methods 0.000 description 1
• 230000003472 neutralizing effect Effects 0.000 description 1
• 239000002547 new drug Substances 0.000 description 1
• 239000012457 nonaqueous media Substances 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 231100000956 nontoxicity Toxicity 0.000 description 1
• 108020004707 nucleic acids Proteins 0.000 description 1
• 102000039446 nucleic acids Human genes 0.000 description 1
• 150000007523 nucleic acids Chemical class 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• 230000009437 off-target effect Effects 0.000 description 1
• 239000012053 oil suspension Substances 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 231100000590 oncogenic Toxicity 0.000 description 1
• 230000002246 oncogenic effect Effects 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• 238000012261 overproduction Methods 0.000 description 1
• 125000005963 oxadiazolidinyl group Chemical group 0.000 description 1
• 125000005882 oxadiazolinyl group Chemical group 0.000 description 1
• 125000001715 oxadiazolyl group Chemical group 0.000 description 1
• 125000005968 oxazolinyl group Chemical group 0.000 description 1
• 125000002971 oxazolyl group Chemical group 0.000 description 1
• 125000003566 oxetanyl group Chemical group 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 150000002926 oxygen Chemical class 0.000 description 1
• 239000006179 pH buffering agent Substances 0.000 description 1
• 235000019629 palatability Nutrition 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 230000006320 pegylation Effects 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 230000035699 permeability Effects 0.000 description 1
• 229940124531 pharmaceutical excipient Drugs 0.000 description 1
• 239000008180 pharmaceutical surfactant Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1
• 230000000649 photocoagulation Effects 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 229940068196 placebo Drugs 0.000 description 1
• 239000000902 placebo Substances 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 150000004804 polysaccharides Chemical class 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 238000010837 poor prognosis Methods 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 229940088953 prinivil Drugs 0.000 description 1
• 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
• 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
• 239000003586 protic polar solvent Substances 0.000 description 1
• 230000035485 pulse pressure Effects 0.000 description 1
• 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
• 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
• 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
• 125000002755 pyrazolinyl group Chemical group 0.000 description 1
• 125000002098 pyridazinyl group Chemical group 0.000 description 1
• 125000001422 pyrrolinyl group Chemical group 0.000 description 1
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• 206010037844 rash Diseases 0.000 description 1
• 239000002464 receptor antagonist Substances 0.000 description 1
• 229940044551 receptor antagonist Drugs 0.000 description 1
• 238000006722 reduction reaction Methods 0.000 description 1
• 238000007634 remodeling Methods 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 230000036387 respiratory rate Effects 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 230000004264 retinal detachment Effects 0.000 description 1
• 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 1
• 210000003705 ribosome Anatomy 0.000 description 1
• 108091008601 sVEGFR Proteins 0.000 description 1
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
• 229940081974 saccharin Drugs 0.000 description 1
• 235000019204 saccharin Nutrition 0.000 description 1
• 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
• 229930195734 saturated hydrocarbon Natural products 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 210000001626 skin fibroblast Anatomy 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 235000010413 sodium alginate Nutrition 0.000 description 1
• 239000000661 sodium alginate Substances 0.000 description 1
• 229940005550 sodium alginate Drugs 0.000 description 1
• 229910000029 sodium carbonate Inorganic materials 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 239000001488 sodium phosphate Substances 0.000 description 1
• 229910000162 sodium phosphate Inorganic materials 0.000 description 1
• 235000011069 sorbitan monooleate Nutrition 0.000 description 1
• 239000001593 sorbitan monooleate Substances 0.000 description 1
• 229940035049 sorbitan monooleate Drugs 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 238000001179 sorption measurement Methods 0.000 description 1
• 229940083466 soybean lecithin Drugs 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 229960001796 sunitinib Drugs 0.000 description 1
• WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 235000012222 talc Nutrition 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 229940108485 tenormin Drugs 0.000 description 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 125000005887 tetrahydrobenzofuranyl group Chemical group 0.000 description 1
• 125000005886 tetrahydrobenzothienyl group Chemical group 0.000 description 1
• 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
• 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
• 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
• 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
• 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
• 125000003831 tetrazolyl group Chemical group 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 231100001274 therapeutic index Toxicity 0.000 description 1
• 125000005304 thiadiazolidinyl group Chemical group 0.000 description 1
• 125000005305 thiadiazolinyl group Chemical group 0.000 description 1
• 125000001113 thiadiazolyl group Chemical group 0.000 description 1
• 125000001984 thiazolidinyl group Chemical group 0.000 description 1
• 125000002769 thiazolinyl group Chemical group 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 238000011830 transgenic mouse model Methods 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• 125000004306 triazinyl group Chemical group 0.000 description 1
• 125000005310 triazolidinyl group Chemical group N1(NNCC1)* 0.000 description 1
• 125000005881 triazolinyl group Chemical group 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
• 230000007306 turnover Effects 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• 238000002562 urinalysis Methods 0.000 description 1
• 238000010200 validation analysis Methods 0.000 description 1
• 210000003556 vascular endothelial cell Anatomy 0.000 description 1
• 239000002525 vasculotropin inhibitor Substances 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 238000005303 weighing Methods 0.000 description 1
• 238000009736 wetting Methods 0.000 description 1